3-{4-[5-(4-trifluoromethyl-phenyl)-2,3-dihydro-indole-1-sulfonyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one | 1033006-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-{4-[5-(4-trifluoromethyl-phenyl)-2,3-dihydro-indole-1-sulfonyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one
• 英文别名: 3-[4-[[5-[4-(trifluoromethyl)phenyl]-2,3-dihydroindol-1-yl]sulfonyl]phenyl]-4H-1,2,4-oxadiazol-5-one
• CAS: 1033006-17-5
• 化学式: C₂₃H₁₆F₃N₃O₄S
• 分子量: 487.459
• InChiKey: LMCCDNWVSAGZOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  96.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-hydroxy-4-[5-(4-trifluoromethyl-phenyl)-2,3-dihydro-indole-1-sulfonyl]-benzamidine 、 氯甲酸苯酯 在 吡啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.42h， 生成 3-{4-[5-(4-trifluoromethyl-phenyl)-2,3-dihydro-indole-1-sulfonyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one
  参考文献：
  名称：

  Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  这项发明涉及磺酰基苯基噁二唑酮及其生理上可接受的盐和生理功能衍生物，显示PPARδ或PPARδ和PPARγ激动剂活性。描述的是式I的化合物，其中基团如所定义，并其生理上可接受的盐和其制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗相关的疾病，以及中枢和外周神经系统的脱髓鞘化和其他神经退行性疾病。

  公开号：

  EP1932843A1

文献信息

• SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：KEIL Stefanie

  公开号：US20090298871A1

  公开（公告）日：2009-12-03

  The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及磺酰基苯基噁唑酮及其生理上可接受的盐和生理上功能衍生物，其显示PPARδ或PPARδ和PPARγ激动剂活性。所描述的是式I的化合物，其中基团如所定义的，并且它们的生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的疾病以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病。
• Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Sanofi-Aventis

  公开号：US08173674B2

  公开（公告）日：2012-05-08

  The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及磺酰基苯基噁唑酮及其生理上可接受的盐和生理上功能衍生物，显示PPARδ或PPARδ和PPARγ激动剂活性。所描述的是式I的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：EP2102198B1

  公开（公告）日：2015-02-25
• US8173674B2
  申请人：——

  公开号：US8173674B2

  公开（公告）日：2012-05-08
• [EN] SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS DE SULFONYL-PHÉNYL-2H-[1,2,4]OXODIAZOL-5-ONE, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2008071311A1

  公开（公告）日：2008-06-19

  [EN] The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
  [FR] L'invention porte sur des sulfonyl-phényl-oxadiazolones et sur leurs sels physiologiquement acceptables et dérivés physiologiquement fonctionnels montrant une activité agoniste de PPARdelta ou de PPARdelta et PPARgamma. On décrit des composés représentés par la formule I, dans laquelle les radicaux sont tels que définis, et leurs sels physiologiquement acceptables et des procédés permettant de les préparer. Les composés sont appropriés pour le traitement et/ou la prévention de troubles du métabolisme des acides gras et des troubles de l'utilisation du glucose ainsi que de troubles dans lesquels la résistance à l'insuline est mise en jeu et la démyélinisation et autres troubles neurodégénératifs du système nerveux central et périphérique.